Biotest AG
BIESFOTCHealthcare
$32.00
+$0.00(+0.00%)
Market Cap$1.6B
P/E Ratio—
52W High$32
52W Low$30.48
Biotest AG (BIESF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BIESF · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2025Report Date: May 12, 2025EPS Actual
-$0.60
Revenue
$0.14B
Fiscal Period
Q2 FY2025
FY ends December
Report Date
May 12, 2025
After Market Close
BIESF reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.19
Rev. $0.35B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.19
Rev. Est.$0.35B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q4 FY2025 | Nov 10, 2025 | — | — | — | — | — | — |
| ◌ Q3 FY2025 | Aug 4, 2025 | — | — | — | — | — | — |
| — Q2 FY2025 | May 12, 2025 | — | -$0.60 | — | $0.14B | — | — |
| — Q1 FY2025 | Feb 26, 2025 | — | -$0.10 | — | $0.21B | — | — |
| — Q4 FY2024 | Nov 14, 2024 | — | -$0.27 | — | $0.17B | — | — |
| — Q3 FY2024 | Jul 30, 2024 | — | $0.26 | — | $0.17B | — | — |
| — Q2 FY2024 | May 7, 2024 | — | $0.80 | — | $0.23B | — | — |
| — Q1 FY2024 | Mar 28, 2024 | — | $1.07 | — | $0.20B | — | — |
Q4 FY2025
Nov 10, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 4, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 12, 2025
EPS Actual
-$0.60
EPS Est.
—
EPS Surpr.
—
Revenue
$0.14B
Q1 FY2025
Feb 26, 2025
EPS Actual
-$0.10
EPS Est.
—
EPS Surpr.
—
Revenue
$0.21B
Q4 FY2024
Nov 14, 2024
EPS Actual
-$0.27
EPS Est.
—
EPS Surpr.
—
Revenue
$0.17B
Q3 FY2024
Jul 30, 2024
EPS Actual
$0.26
EPS Est.
—
EPS Surpr.
—
Revenue
$0.17B
Q2 FY2024
May 7, 2024
EPS Actual
$0.80
EPS Est.
—
EPS Surpr.
—
Revenue
$0.23B
Q1 FY2024
Mar 28, 2024
EPS Actual
$1.07
EPS Est.
—
EPS Surpr.
—
Revenue
$0.20B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2025 | May 12, 2025 | — | $32.00 | $32.00 | +0.00% |
| — Q1 FY2025 | Feb 26, 2025 | — | $30.48 | $30.48 | +0.00% |
| — Q4 FY2024 | Nov 14, 2024 | — | $30.48 | $30.48 | +0.00% |
| — Q3 FY2024 | Jul 30, 2024 | — | $30.48 | $30.48 | +0.00% |
| — Q2 FY2024 | May 7, 2024 | — | $30.48 | $30.48 | +0.00% |
| — Q1 FY2024 | Mar 28, 2024 | — | $30.48 | $30.48 | +0.00% |
| — Q3 FY2023 | Sep 30, 2023 | — | $34.60 | $34.60 | +0.00% |
| — Q2 FY2023 | Jun 30, 2023 | — | $34.60 | $34.60 | +0.00% |
Q2 FY2025+0.00%
Report Date
May 12, 2025
EPS Beat/Miss
—
Price Before
$32.00
Price After
$32.00
Q1 FY2025+0.00%
Report Date
Feb 26, 2025
EPS Beat/Miss
—
Price Before
$30.48
Price After
$30.48
Q4 FY2024+0.00%
Report Date
Nov 14, 2024
EPS Beat/Miss
—
Price Before
$30.48
Price After
$30.48
Q3 FY2024+0.00%
Report Date
Jul 30, 2024
EPS Beat/Miss
—
Price Before
$30.48
Price After
$30.48
Q2 FY2024+0.00%
Report Date
May 7, 2024
EPS Beat/Miss
—
Price Before
$30.48
Price After
$30.48
Q1 FY2024+0.00%
Report Date
Mar 28, 2024
EPS Beat/Miss
—
Price Before
$30.48
Price After
$30.48
Q3 FY2023+0.00%
Report Date
Sep 30, 2023
EPS Beat/Miss
—
Price Before
$34.60
Price After
$34.60
Q2 FY2023+0.00%
Report Date
Jun 30, 2023
EPS Beat/Miss
—
Price Before
$34.60
Price After
$34.60
Beat Rate0 / 8 quarters
Largest Move+0.00% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BIESF ends December
Biotest AG (BIESF) most recently reported earnings on May 12, 2025 for Q2 FY2025, posting EPS of $-0.60 (in line with the analyst consensus of —). The next BIESF earnings date is expected around September 1, 2026.
Each quarter, investors track BIESF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BIESF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BIESF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BIESF earnings · 4 questionsBiotest AG's next earnings report is expected around September 1, 2026. BIESF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BIESF historically reports after market close (AMC).
BIESF earnings datewhen is BIESF earningsBIESF next earnings datewhen does BIESF report earningsBIESF earnings calendar
▸ Source: FMP · Biotest AG SEC filings · US GAAP · Biotest AG SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026